Evidence map›Paper›PMID 35852988›Full record

ArticleJournal of clinical laboratory analysis2022

A multicenter performance evaluation of the new Elecsys Vitamin D total III assay versus reference isotope dilution liquid chromatography tandem mass spectrometry and commercially available comparators.

Peter Findeisen, Marta Leis, Garnet Bendig, Jill Grimme, Elizabeth Moser, Christian Vogl, Robert Christenson

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Peter FindeisenMVZ Labor Dr. Limbach & Kollegen, Heidelberg, Germany.
Marta LeisTRIGA-S, Habach, Germany.
Garnet BendigRoche Diagnostics GmbH, Penzberg, Germany.
Jill GrimmeRoche Diagnostics, Indianapolis, Indiana, USA.
Elizabeth MoserRoche Diagnostics, Indianapolis, Indiana, USA.
Christian VoglRoche Diagnostics GmbH, Penzberg, Germany.
Robert ChristensonUniversity of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-2612-9083
Roche Pharma AG (Germany) · DERoche (United States) · USMedizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer · DEStadtkrankenhaus Schwabach · DEUniversity of Maryland, Baltimore · US

Funding

Roche Diagnostics International Ltd (Rotkreuz, Switzerland)
6 · The paper itself

Abstract

backgroundVitamin D deficiency/insufficiency and toxicity are worldwide issues; thus, accurate diagnostic assays are required to measure vitamin D. We evaluated the performance of the new Elecsys

methodsRepeatability and intermediate precision of the Elecsys Vitamin D total III assay (cobas e 601 analyzer) were evaluated at three sites using five human serum pools (HSPs) and two PreciControls (five-day model, one reagent lot [CLSI-EP05-A3]) and compared against prespecified acceptance criteria. A serum verification panel, with reference isotope dilution liquid chromatography tandem mass spectrometry (ID-LC-MS/MS) values, was used for comparator assay/concordance studies at two sites, assessed using unweighted Deming regression. Testing of serum vs. plasma on the Elecsys assay was conducted at one site using samples from healthy adults; assessed using Passing-Bablok regression.

resultsRepeatability (HSP1 [16.8-18.4 ng/ml], SD 0.87-1.07; HSP5 [94.5-98.0 ng/ml], CV 1.58%-2.76%) and intermediate precision (HSP1, SD 1.14-1.77; HSP5, CV 2.00%-4.13%) met acceptance criteria across sites. Agreement was observed between the Elecsys assay and (i) the ID-LC-MS/MS verification panel (slope, 0.936-1.01; Pearson's r, 0.960-0.986) and (ii) comparator assays (slope, 0.921-1.15; Pearson's r, 0.958-0.982). The Elecsys assay correctly assigned the highest combined percentage of samples to deficient (100%) and insufficient (89.5%) vitamin D categories vs. comparator assays and demonstrated comparable performance in serum and plasma (y = 0.103 + 0.984x).

conclusionsThe Elecsys Vitamin D total III assay demonstrated good analytical performance and compared favorably with other assays, supporting its use in clinical practice.

Indexed as

Tandem Mass SpectrometryVitamin DAdultChromatography, LiquidHumansImmunoassayIsotopesVitaminsIsotopesVitamin DVitaminsanalytical performanceassaymethod comparisonvitamin D

Identifiers

PMID35852988
PMCPMC9459274
OpenAlexW4285795398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.